# OnCo record nct06793215 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06793215/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06793215", "NCT06793215" ;
  schema:name "A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip"@en ;
  schema:alternateName "Krascendo 2"@en ;
  schema:description "A phase 3 trial of Divarasib, Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06793215/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06793215> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-10-24" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> .